BioCryst to Report First Quarter 2021 Financial Results on May 6
April 22 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will report its first quarter 2021 financial results on
Thursday, May 6, 2021.
BioCryst management will host a conference call
and webcast at 8:30 a.m. ET that day to discuss the financial
results and provide a corporate update.
The live call may be accessed by dialing
877-303-8027 for domestic callers and 760-536-5165 for
international callers and using conference ID # 2660434. A live
webcast of the call and any slides will be available online at the
investors section of the company website at www.biocryst.com. A
telephone replay of the call will be available by dialing
855-859-2056 for domestic callers or 404-537-3406 for international
callers and entering the conference ID # 2660434.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States and Japan
for the prevention of HAE attacks in adults and pediatric patients
12 years and older, and under regulatory review for approval in the
European Union and United Kingdom. BioCryst has several ongoing
development programs including BCX9930, an oral Factor D inhibitor
for the treatment of complement-mediated diseases, BCX9250, an
ALK-2 inhibitor for the treatment of fibrodysplasia ossificans
progressiva, and galidesivir, a potential treatment for Marburg
virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a
viral neuraminidase inhibitor for the treatment of influenza, has
received regulatory approval in the U.S., Canada, Australia, Japan,
Taiwan and Korea. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the company’s website
at www.biocryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024